Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.
 
> Neferine [2292-16-2]

Neferine [2292-16-2]

Imprimir Imprimir
Please log in

Referência HY-N0441-5mg

Tamanho : 5mg

Marca : MedChemExpress

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Description

Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation.

IC50 & Target[1]

p65

 

Autophagy

 

Cellular Effect
Cell Line Type Value Description References
3T3-L1 IC50
4.5 μM
Compound: 8
Anti-adipogenic activity in mouse 3T3-L1 cells transfected with Lenti-PPARgamma-Luc reporter assessed as inhibition of PPARgamma expression by luminescence based microplate reader analysis
Anti-adipogenic activity in mouse 3T3-L1 cells transfected with Lenti-PPARgamma-Luc reporter assessed as inhibition of PPARgamma expression by luminescence based microplate reader analysis
[PMID: 38483204]
ECa-109 cell line IC50
3794 nM
Compound: NEF
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
[PMID: 36892076]
In Vitro

Neferine down regulates hypoxia induced NF-κB p65 nuclear translocation and COX-2 expressions[1]. Neferine reduces high-glucose-induced collagen production and inhibits TGF-β1-Smad, ERK and p38 MAPK signaling activation in cardiac fibroblasts. Cardiac fibroblasts (CFs) are cultured in HG medium with varying concentrations of Neferine (1, 2, or 5 μM). CCK-8 assays are carried out at different time points (24, 48, and 72 h). Compared with normal glucose (NG) and osmotic control (OC) treatments, High glucose (30 mM) treatment significantly increases the proliferation of CFs in a time-dependent manner (P<0.05). High glucose (HG)-induced CF proliferation is markedly attenuated by Neferine treatment at either 2 or 5 μM compared with vehicle treatment. However, 1 μM Neferine does not inhibit HG-induced proliferation of CFs. Therefore, 2 and 5 μM Neferine are used in the remaining experiments[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Neferine Related Antibodies

Solvant et solubilité
In Vitro: 

DMSO : 125 mg/mL (200.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6006 mL 8.0029 mL 16.0059 mL
5 mM 0.3201 mL 1.6006 mL 3.2012 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.
Pureté et documentation
Références

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT
A10375-50
Evista [82640-04-8]
 50mg 
A14743-5
Neferine [2292-16-2]
 5mg 
HY-13738A-100mg
Raloxifene (hydrochloride) [82640-04-8]
 100mg